BLTE · Belite Bio, Inc
$147.33
-1.96% last session
End-of-day data · close of 2026-10-23
Market cap
$6B
Enterprise value
—
Trailing P/E
—
Forward P/E
65.2
Dividend yield
0.0%
Beta
-1.23
Avg volume
0M
Employees
0K
Daily Change %
-1.96%
5 Days Change
5.25%
10 Days Change
-1.05%
30 Days Change
-10.91%
60 Days Change
-5.41%
Month to Day Change
-7.80%
Year to Day Change
-6.06%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — BLTE
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-15
Latest call per bank · past 12 months
Morgan Stanley
Overweight$206
+39.8% vs priceBank of America
Buy$195
+32.4% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-15 | HC Wainwright & Co. | Reiterates | Buy | $245 |
| 2026-09-09 | Mizuho | Maintains | Outperform | $220 → $234 |
| 2026-09-08 | HC Wainwright & Co. | Maintains | Buy | $214 → $245 |
| 2026-09-04 | Canaccord Genuity | Initiates | Buy | $0.00 → $303 |
| 2026-08-14 | Morgan Stanley | Maintains | Overweight | $201 → $206 |
| 2026-08-14 | Cantor Fitzgerald | Maintains | Overweight | $266 → $270 |
| 2026-08-12 | HC Wainwright & Co. | Maintains | Buy | $200 → $214 |
| 2026-06-15 | HC Wainwright & Co. | Reiterates | Buy | $200 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- neutral: RSI (14): RSI is 39 — neutral momentum, neither overbought nor oversold.
- bearish: Price vs 50-day MA: Trading 9.6% below the 50-day MA ($163.00).
- bearish: Price vs 200-day MA: Trading 8.3% below the 200-day MA ($160.59).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bearish: MACD (12,26,9): MACD histogram is negative (-0.38) — short-term momentum is fading.
- neutral: 52-week range: Price sits between the 52-week low ($92.22) and high ($193.61).
BLTE Price Chart
Loading chart for BLTE…
Fundamentals
About Belite Bio, Inc
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$133B 18.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 6.5% YTD
MRNA
Moderna, Inc.
$80B 587.1% YTD
ARGX
argenx SE
$55B 4.1% YTD
ONC
BeOne Medicines Ltd.
$43B 25.8% YTD
RVMD
Revolution Medicines, Inc.
$40B 135.6% YTD
RPRX
Royalty Pharma plc
$37B 67.3% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.